Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederik Marmé

Showing results (1-10 of 175) with videos related to

Pageof 18
Sort By:
Oncology Research and Treatment|June 5, 2016
Immunotherapy in Breast CancerFrederik Marmé
Journal of Gynecologic Oncology|February 3, 2025
PRIMA: captivated by the wizard of OS?Frederik Marmé
Oncology Research and Treatment|December 16, 2021
Antibody-Drug Conjugates for Breast CancerFrederik Marmé
Cancer Treatment Reviews|January 11, 2024
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancerKomal Jhaveri, Frederik Marmé
Onkologie|January 31, 2012
Personalized therapy in breast cancerFrederik Marmé, Andreas Schneeweiss
Breast Care (Basel, Switzerland)|May 20, 2021
Treatment of Luminal Metastatic Breast Cancer beyond CDK4/6 Inhibition: Is There a Standard of Care in Clinical Practice?Athanasios Mavratzas, Frederik Marmé
Future Oncology (London, England)|September 23, 2020
Alpelisib in the treatment of metastatic HR+ breast cancer with <i>PIK3CA</i> mutationsAthanasios Mavratzas, Frederik Marmé
Breast Care (Basel, Switzerland)|November 12, 2015
Targeted Therapies in Triple-Negative Breast CancerFrederik Marmé, Andreas Schneeweiss
Lancet (London, England)|June 21, 2025
Targeting the glucocorticoid receptor in relapsed ovarian cancer: a new pathway and standard treatment option in ovarian cancerPhilipp Harter, Frederik Marmé
Future Oncology (London, England)|September 7, 2022
Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizonJenny Furlanetto, Frederik Marmé, Sibylle Loibl
Pageof 18

Showing results (1-10 of 175) with videos related to

Sort By:
Pageof 18
Oncology Research and Treatment|June 5, 2016
Immunotherapy in Breast CancerFrederik Marmé
Journal of Gynecologic Oncology|February 3, 2025
PRIMA: captivated by the wizard of OS?Frederik Marmé
Oncology Research and Treatment|December 16, 2021
Antibody-Drug Conjugates for Breast CancerFrederik Marmé
Cancer Treatment Reviews|January 11, 2024
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancerKomal Jhaveri, Frederik Marmé
Onkologie|January 31, 2012
Personalized therapy in breast cancerFrederik Marmé, Andreas Schneeweiss
Breast Care (Basel, Switzerland)|May 20, 2021
Treatment of Luminal Metastatic Breast Cancer beyond CDK4/6 Inhibition: Is There a Standard of Care in Clinical Practice?Athanasios Mavratzas, Frederik Marmé
Future Oncology (London, England)|September 23, 2020
Alpelisib in the treatment of metastatic HR+ breast cancer with <i>PIK3CA</i> mutationsAthanasios Mavratzas, Frederik Marmé
Breast Care (Basel, Switzerland)|November 12, 2015
Targeted Therapies in Triple-Negative Breast CancerFrederik Marmé, Andreas Schneeweiss
Lancet (London, England)|June 21, 2025
Targeting the glucocorticoid receptor in relapsed ovarian cancer: a new pathway and standard treatment option in ovarian cancerPhilipp Harter, Frederik Marmé
Future Oncology (London, England)|September 7, 2022
Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizonJenny Furlanetto, Frederik Marmé, Sibylle Loibl
Pageof 18